{"title":"Recovery \u0026 Repair","description":"\u003cp\u003ePeptides studied for their role in tissue repair, wound healing, and recovery processes. Includes BPC-157, TB-500, GHK-Cu, KPV, and related compounds.\u003c\/p\u003e","products":[{"product_id":"tirzepatide-glp-1-gip-peptide-vial-5mg-lyophilisate","title":"Tirzepatide GLP-1\/GIP Peptide Vial Lyophilisate For Lab Research","description":"\u003ch1\u003eTirzepatide (GLP-1 \/ GIP Dual Agonist)\u003c\/h1\u003e\n\u003chr\u003e\n\u003ch2\u003eOverview\u003c\/h2\u003e\n\u003cp\u003eTirzepatide is a synthetic peptide-based medication designed as a dual agonist of glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptors.\u003c\/p\u003e\n\u003cp\u003eIn research and clinical contexts, tirzepatide is primarily studied for its effects on glucose regulation, insulin sensitivity, appetite signaling, and body weight modulation. It represents a newer class of incretin-based therapies that integrate two metabolic pathways into a single molecular framework.\u003c\/p\u003e\n\u003cp\u003eUnlike earlier GLP-1 receptor agonists, tirzepatide simultaneously targets both GLP-1 and GIP signaling systems, which are central to postprandial metabolic regulation.\u003c\/p\u003e\n\u003chr\u003e\n\u003ch2\u003eMechanism of Action\u003c\/h2\u003e\n\u003cp\u003eTirzepatide acts through dual incretin receptor activation:\u003c\/p\u003e\n\u003chr\u003e\n\u003ch3\u003e1. GLP-1 Receptor Activation\u003c\/h3\u003e\n\u003cp\u003e✓ Enhances glucose-dependent insulin secretion\u003cbr\u003e✓ Suppresses glucagon release during hyperglycemia\u003cbr\u003e✓ Slows gastric emptying (delayed nutrient absorption)\u003cbr\u003e✓ Promotes satiety signaling via central nervous system pathways\u003c\/p\u003e\n\u003chr\u003e\n\u003ch3\u003e2. GIP Receptor Activation\u003c\/h3\u003e\n\u003cp\u003e✓ Enhances insulin secretion in glucose-dependent manner\u003cbr\u003e✓ Modulates lipid metabolism and energy storage pathways\u003cbr\u003e✓ Influences adipose tissue function in metabolic models\u003cbr\u003e✓ Works synergistically with GLP-1 signaling to improve glycemic control\u003c\/p\u003e\n\u003chr\u003e\n\u003ch3\u003e3. Combined Dual Incretin Effect\u003c\/h3\u003e\n\u003cp\u003eWhen both pathways are activated simultaneously, research and clinical studies show:\u003c\/p\u003e\n\u003cp\u003e✓ Improved glycemic control compared to single-pathway agents\u003cbr\u003e✓ Enhanced appetite regulation and reduced caloric intake\u003cbr\u003e✓ Modulation of body weight and fat mass distribution\u003cbr\u003e✓ Improved metabolic efficiency in insulin-resistant states\u003c\/p\u003e\n\u003chr\u003e\n\u003ch2\u003eResearch and Clinical Applications\u003c\/h2\u003e\n\u003cp\u003eTirzepatide is studied extensively in metabolic medicine:\u003c\/p\u003e\n\u003chr\u003e\n\u003ch3\u003eType 2 Diabetes Research\u003c\/h3\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003cp\u003eGlycemic control improvement in insulin resistance models\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp\u003eHbA1c reduction mechanisms\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp\u003eBeta-cell function support in experimental and clinical studies\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003chr\u003e\n\u003ch3\u003eObesity and Body Weight Regulation\u003c\/h3\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003cp\u003eAppetite suppression and satiety signaling\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp\u003eReduction of adipose tissue mass\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp\u003eEnergy intake and expenditure balance studies\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp\u003eCentral nervous system appetite regulation pathways\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003chr\u003e\n\u003ch3\u003eCardiometabolic Research\u003c\/h3\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003cp\u003eLipid profile modulation\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp\u003eInsulin sensitivity improvement\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp\u003eCardiovascular risk factor reduction models\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp\u003eMetabolic syndrome intervention studies\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003chr\u003e\n\u003ch3\u003eEndocrine and Incretin Biology\u003c\/h3\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003cp\u003eDual incretin receptor synergy research\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp\u003eGut–pancreas–brain axis signaling\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp\u003eHormonal regulation of postprandial metabolism\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003chr\u003e\n\u003ch2\u003eTechnical Specifications\u003c\/h2\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eProperty\u003c\/th\u003e\n\u003cth\u003eTirzepatide\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eFunctional Class\u003c\/td\u003e\n\u003ctd\u003eDual GLP-1 \/ GIP receptor agonist\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePeptide Length\u003c\/td\u003e\n\u003ctd\u003e39 amino acids\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMolecular Weight\u003c\/td\u003e\n\u003ctd\u003e~4,813 Da\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eStructural Modification\u003c\/td\u003e\n\u003ctd\u003eFatty acid chain for albumin binding\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAdministration (clinical use)\u003c\/td\u003e\n\u003ctd\u003eSubcutaneous injection\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eHalf-life\u003c\/td\u003e\n\u003ctd\u003e~5 days (enables weekly dosing)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePrimary Targets\u003c\/td\u003e\n\u003ctd\u003eGLP-1R and GIPR\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMechanism Type\u003c\/td\u003e\n\u003ctd\u003eIncretin-based metabolic regulator\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003chr\u003e\n\u003ch2\u003eStability \u0026amp; Storage\u003c\/h2\u003e\n\u003ch3\u003eLyophilized \/ Unreconstituted Form\u003c\/h3\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003cp\u003eStore at \u003cstrong\u003e-20°C\u003c\/strong\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp\u003eProtect from light and moisture\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp\u003eAvoid repeated freeze-thaw cycles\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp\u003eMaintain sterile pharmaceutical-grade handling\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003chr\u003e\n\u003ch3\u003eReconstituted \/ Injectable Form\u003c\/h3\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003cp\u003eStore at \u003cstrong\u003e2–8°C (refrigerated)\u003c\/strong\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp\u003eLimited stability depending on formulation\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp\u003eUse within defined clinical or research timeframes\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp\u003eAvoid agitation and temperature fluctuations\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003chr\u003e\n\u003ch2\u003ePharmacokinetic Notes (Research Data)\u003c\/h2\u003e\n\u003cp\u003eIn clinical and experimental studies:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003cp\u003eLong half-life due to albumin binding modification\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp\u003eSteady-state achieved with weekly administration\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp\u003eSustained receptor activation across GLP-1 and GIP pathways\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp\u003eDose-dependent metabolic and appetite regulation effects\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003chr\u003e\n\u003ch2\u003eSafety and Physiological Considerations (Research Context)\u003c\/h2\u003e\n\u003cp\u003eObserved in clinical research:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003cp\u003eGastrointestinal side effects (dose-dependent)\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp\u003eAppetite suppression mediated via central pathways\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp\u003eImproved insulin sensitivity in metabolic populations\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp\u003eHormonal feedback remains glucose-dependent rather than constitutive\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003chr\u003e\n\u003ch2\u003eResearch Keywords \/ PubMed Search Terms\u003c\/h2\u003e\n\u003ch3\u003eCore Topics\u003c\/h3\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003cp\u003etirzepatide GLP-1 GIP dual agonist\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp\u003eincretin receptor agonists metabolism\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp\u003eglucose-dependent insulin secretion peptide\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp\u003ealbumin-bound peptide pharmacokinetics\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003chr\u003e\n\u003ch3\u003eMetabolic Research\u003c\/h3\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003cp\u003eobesity GLP-1 GIP weight loss\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp\u003einsulin resistance incretin therapy\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp\u003eappetite regulation central nervous system incretins\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp\u003ecardiometabolic risk reduction peptides\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003chr\u003e\n\u003ch3\u003eClinical Context\u003c\/h3\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003cp\u003eSURPASS clinical trials tirzepatide\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp\u003etype 2 diabetes incretin dual agonist therapy\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp\u003emetabolic syndrome incretin drugs\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003chr\u003e\n\u003ch2\u003eResearch Use \/ Context Disclaimer\u003c\/h2\u003e\n\u003cp\u003eThis material is intended for scientific and educational reference based on published literature and clinical research data.\u003c\/p\u003e\n\u003cp\u003eTirzepatide in approved formulations is a prescription medication in many jurisdictions and must be used only under appropriate medical supervision.\u003c\/p\u003e\n\u003cp\u003eThis description:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003cp\u003eIs not medical advice\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp\u003eIs not a dosing guide\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp\u003eIs not intended to promote unsupervised use\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp\u003eReflects research and clinical trial data only.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e","brand":"NordBioLab","offers":[{"title":"10","offer_id":57689567592780,"sku":null,"price":129.0,"currency_code":"EUR","in_stock":false},{"title":"30","offer_id":57689567625548,"sku":null,"price":279.0,"currency_code":"EUR","in_stock":false}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/1058\/8363\/1948\/files\/nordbiolab-tirzepatide-10mg-holographic-vial.png?v=1780408554"},{"product_id":"tesamorelin-peptide-vial-5mg-lyophilisate","title":"Tesamorelin Peptide Vial Lyophilisate For Lab Research","description":"\u003ch1\u003eTesamorelin\u003c\/h1\u003e\n\u003chr\u003e\n\u003ch2\u003eOverview\u003c\/h2\u003e\n\u003cp\u003eTesamorelin is a synthetic peptide analog of growth hormone-releasing hormone (GHRH) designed to stimulate endogenous growth hormone secretion via pituitary GHRH receptor activation.\u003c\/p\u003e\n\u003cp\u003eIn scientific and clinical research contexts, Tesamorelin is primarily studied for its effects on growth hormone (GH) pulsatility, downstream IGF-1 signaling, and metabolic regulation—particularly in relation to visceral adipose tissue modulation.\u003c\/p\u003e\n\u003cp\u003eUnlike shorter experimental peptides, Tesamorelin has been investigated in regulated clinical settings, especially in the context of HIV-associated lipodystrophy.\u003c\/p\u003e\n\u003chr\u003e\n\u003ch2\u003eMechanism of Action\u003c\/h2\u003e\n\u003cp\u003eTesamorelin acts through the endogenous growth hormone regulatory axis:\u003c\/p\u003e\n\u003ch3\u003e1. GHRH Receptor Activation\u003c\/h3\u003e\n\u003cp\u003e✓ Binds to growth hormone-releasing hormone receptors in the anterior pituitary\u003cbr\u003e✓ Stimulates pulsatile secretion of endogenous growth hormone\u003cbr\u003e✓ Enhances physiological GH release patterns rather than continuous stimulation\u003c\/p\u003e\n\u003chr\u003e\n\u003ch3\u003e2. IGF-1 Axis Modulation\u003c\/h3\u003e\n\u003cp\u003e✓ Increases circulating IGF-1 levels via GH-mediated hepatic signaling\u003cbr\u003e✓ Supports downstream anabolic and metabolic pathways in research and clinical studies\u003cbr\u003e✓ Influences lipid and glucose metabolism indirectly through GH\/IGF-1 axis\u003c\/p\u003e\n\u003chr\u003e\n\u003ch3\u003e3. Lipid Metabolism Effects (Clinical Research Focus)\u003c\/h3\u003e\n\u003cp\u003e✓ Studied for reduction of visceral adipose tissue (VAT)\u003cbr\u003e✓ Modulates lipid mobilization and fat distribution patterns\u003cbr\u003e✓ Investigated in metabolic syndrome-related models\u003c\/p\u003e\n\u003chr\u003e\n\u003ch3\u003e4. Endocrine Feedback Regulation\u003c\/h3\u003e\n\u003cp\u003e✓ Preserves physiological feedback loops of hypothalamic–pituitary axis\u003cbr\u003e✓ Promotes episodic GH secretion rather than constant elevation\u003cbr\u003e✓ Maintains regulatory endocrine signaling dynamics in studied models\u003c\/p\u003e\n\u003chr\u003e\n\u003ch2\u003eResearch and Clinical Applications\u003c\/h2\u003e\n\u003cp\u003eTesamorelin has been studied in both clinical and experimental contexts:\u003c\/p\u003e\n\u003ch3\u003eMetabolic Research\u003c\/h3\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003cp\u003eVisceral fat reduction mechanisms\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp\u003eLipid metabolism regulation\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp\u003eInsulin sensitivity and glucose homeostasis studies\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp\u003eObesity-related endocrine signaling models\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003chr\u003e\n\u003ch3\u003eEndocrine Research\u003c\/h3\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003cp\u003eGrowth hormone pulsatility regulation\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp\u003eIGF-1 axis modulation\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp\u003ePituitary signaling pathway studies\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp\u003eHypothalamic–pituitary axis feedback research\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003chr\u003e\n\u003ch3\u003eHIV-Associated Lipodystrophy (Clinical Context)\u003c\/h3\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003cp\u003eReduction of visceral adipose tissue in HIV-related metabolic changes\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp\u003eBody composition normalization studies\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp\u003eMetabolic complication management research\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003chr\u003e\n\u003ch3\u003eAging and Regenerative Research (Experimental Interest)\u003c\/h3\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003cp\u003eAge-related GH decline models\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp\u003eBody composition changes in aging\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp\u003eProtein metabolism and lean mass maintenance studies\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003chr\u003e\n\u003ch2\u003eTechnical Specifications\u003c\/h2\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eProperty\u003c\/th\u003e\n\u003cth\u003eTesamorelin\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003ePeptide Class\u003c\/td\u003e\n\u003ctd\u003eGHRH Analog\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eFunctional Target\u003c\/td\u003e\n\u003ctd\u003eGHRH receptor (pituitary)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAmino Acid Length\u003c\/td\u003e\n\u003ctd\u003e44 amino acids\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMolecular Weight\u003c\/td\u003e\n\u003ctd\u003e~5,535 Da\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eModification\u003c\/td\u003e\n\u003ctd\u003eStabilized GHRH analog (N-terminal modifications)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePrimary Effect\u003c\/td\u003e\n\u003ctd\u003eStimulates endogenous GH release\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAdministration Route (clinical studies)\u003c\/td\u003e\n\u003ctd\u003eSubcutaneous\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eHalf-life\u003c\/td\u003e\n\u003ctd\u003eShort systemic duration with extended biological effect via GH axis\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003chr\u003e\n\u003ch2\u003eStability \u0026amp; Storage\u003c\/h2\u003e\n\u003ch3\u003eLyophilized Form\u003c\/h3\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003cp\u003eStore at \u003cstrong\u003e-20°C\u003c\/strong\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp\u003eProtect from moisture and light exposure\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp\u003eMaintain sealed sterile environment\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp\u003eAvoid repeated freeze-thaw cycles\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003chr\u003e\n\u003ch3\u003eReconstituted Solution\u003c\/h3\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003cp\u003eStore at \u003cstrong\u003e2–8°C for short-term use\u003c\/strong\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp\u003eLimited stability depending on solvent and sterility conditions\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp\u003eTypically used within defined research or clinical handling windows\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp\u003eDegradation increases with temperature and microbial exposure\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003chr\u003e\n\u003ch2\u003ePharmacokinetic Notes (Research Data)\u003c\/h2\u003e\n\u003cp\u003eIn studied models:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003cp\u003eRapid binding to pituitary GHRH receptors after administration\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp\u003eInduces physiological GH pulsatility rather than sustained elevation\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp\u003eSecondary increase in IGF-1 with hepatic mediation\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp\u003eShort plasma half-life but prolonged endocrine downstream effects\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003chr\u003e\n\u003ch2\u003eSafety and Physiological Considerations (Research Context)\u003c\/h2\u003e\n\u003cp\u003eObserved in clinical studies:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003cp\u003eGH\/IGF-1 elevation is dose-dependent\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp\u003ePotential metabolic effects include changes in insulin sensitivity\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp\u003eEndocrine feedback mechanisms remain active\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp\u003eEffects are mediated through endogenous hormone systems rather than direct receptor agonism outside GH axis\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003chr\u003e\n\u003ch2\u003eResearch Keywords \/ PubMed Search Terms\u003c\/h2\u003e\n\u003ch3\u003eCore Topics\u003c\/h3\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003cp\u003eTesamorelin GHRH analog\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp\u003egrowth hormone releasing hormone peptide\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp\u003eGH IGF-1 axis modulation\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp\u003epituitary growth hormone secretion\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003chr\u003e\n\u003ch3\u003eMetabolic Research\u003c\/h3\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003cp\u003evisceral adipose tissue reduction GH\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp\u003elipid metabolism growth hormone analog\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp\u003einsulin sensitivity GH axis\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp\u003ebody composition endocrine regulation\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003chr\u003e\n\u003ch3\u003eClinical Context\u003c\/h3\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003cp\u003eHIV-associated lipodystrophy Tesamorelin\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp\u003eEgrifta (brand context) clinical trials\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp\u003evisceral fat reduction therapy GH analog\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003chr\u003e\n\u003ch2\u003eResearch Use Only Disclaimer\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003eFOR RESEARCH USE ONLY\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThis material is intended exclusively for laboratory and scientific research by qualified professionals.\u003c\/p\u003e\n\u003cp\u003eThis compound:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003cp\u003eIs not approved for unsupervised human use outside regulated indications\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp\u003eIs not intended to diagnose, treat, cure, or prevent any disease in this context\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp\u003eIs not a dietary supplement\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp\u003eMust only be handled in appropriate clinical or laboratory research environments\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eAll information reflects published scientific and clinical literature. Outcomes observed in studies may vary and are not guaranteed to translate across populations or use cases.\u003c\/p\u003e","brand":"NordBioLab","offers":[{"title":"5","offer_id":57689556746572,"sku":null,"price":79.0,"currency_code":"EUR","in_stock":false},{"title":"10","offer_id":57689556779340,"sku":null,"price":139.0,"currency_code":"EUR","in_stock":false}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/1058\/8363\/1948\/files\/nordbiolab-tesamorelin-holographic-vial.png?v=1780408396"},{"product_id":"cjc-1295-no-dac-ipamorelin-peptide-vial-lyophilisate-for-lab-research","title":"CJC-1295 (NO DAC) + Ipamorelin Peptide Vial Lyophilisate For Lab Research","description":"\u003ch1\u003eCJC-1295 (No DAC) + Ipamorelin\u003c\/h1\u003e\n\u003chr\u003e\n\u003ch2\u003eOverview\u003c\/h2\u003e\n\u003cp\u003eCJC-1295 (No DAC) and Ipamorelin are synthetic peptides commonly studied in endocrine and growth hormone research. When used together in experimental settings, they are often investigated for their complementary effects on growth hormone (GH) pulsatility and secretion dynamics.\u003c\/p\u003e\n\u003cp\u003eCJC-1295 (No DAC) is a modified analog of growth hormone-releasing hormone (GHRH 1–29) designed to stimulate endogenous GH release through pituitary GHRH receptor activation, with a shorter half-life compared to its DAC-modified counterpart.\u003c\/p\u003e\n\u003cp\u003eIpamorelin is a selective growth hormone secretagogue (GHS) and ghrelin receptor (GHS-R1a) agonist. It is studied for its ability to stimulate GH release in a more selective manner, with minimal reported activity on prolactin or cortisol pathways in experimental models.\u003c\/p\u003e\n\u003cp\u003eTogether, these peptides are frequently examined in research exploring synergistic stimulation of pulsatile growth hormone release.\u003c\/p\u003e\n\u003chr\u003e\n\u003ch2\u003eMechanism of Action\u003c\/h2\u003e\n\u003cp\u003eCJC-1295 (No DAC) and Ipamorelin act on distinct but complementary pathways involved in growth hormone regulation.\u003c\/p\u003e\n\u003ch3\u003eCJC-1295 (No DAC)\u003c\/h3\u003e\n\u003cp\u003e✓ Mimics endogenous GHRH (growth hormone-releasing hormone)\u003c\/p\u003e\n\u003cp\u003e✓ Binds to GHRH receptors in the anterior pituitary\u003c\/p\u003e\n\u003cp\u003e✓ Stimulates pulsatile secretion of growth hormone\u003c\/p\u003e\n\u003cp\u003e✓ Enhances downstream IGF-1 signaling in experimental models\u003c\/p\u003e\n\u003cp\u003e✓ Shorter systemic activity compared to DAC-modified versions\u003c\/p\u003e\n\u003chr\u003e\n\u003ch3\u003eIpamorelin\u003c\/h3\u003e\n\u003cp\u003e✓ Selective agonist of ghrelin receptor (GHS-R1a)\u003c\/p\u003e\n\u003cp\u003e✓ Stimulates growth hormone release from somatotroph cells\u003c\/p\u003e\n\u003cp\u003e✓ Minimal observed activity on cortisol or prolactin in studies\u003c\/p\u003e\n\u003cp\u003e✓ Supports GH pulse amplitude in research models\u003c\/p\u003e\n\u003chr\u003e\n\u003ch3\u003eCombined Research Mechanism\u003c\/h3\u003e\n\u003cp\u003eWhen studied together, CJC-1295 (No DAC) and Ipamorelin are hypothesized to:\u003c\/p\u003e\n\u003cp\u003e✓ Activate complementary GH secretion pathways (GHRH + ghrelin axis)\u003c\/p\u003e\n\u003cp\u003e✓ Enhance pulsatile GH release patterns\u003c\/p\u003e\n\u003cp\u003e✓ Increase overall GH secretion magnitude in experimental settings\u003c\/p\u003e\n\u003cp\u003e✓ Improve temporal GH signaling dynamics (pulse frequency and amplitude)\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eImportant:\u003c\/strong\u003e These mechanisms are based on preclinical and limited clinical research. Synergistic effects are still under investigation.\u003c\/p\u003e\n\u003chr\u003e\n\u003ch2\u003eResearch Applications\u003c\/h2\u003e\n\u003cp\u003eCJC-1295 (No DAC) + Ipamorelin are commonly studied in the following research domains:\u003c\/p\u003e\n\u003ch3\u003eEndocrine Research\u003c\/h3\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003cp\u003eGrowth hormone secretion dynamics\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp\u003ePituitary signaling pathways\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp\u003eGHRH and ghrelin receptor interaction studies\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp\u003eHormonal pulsatility modeling\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch3\u003eMetabolic Research\u003c\/h3\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003cp\u003eIGF-1 axis regulation\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp\u003eLipid metabolism pathways\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp\u003eGlucose homeostasis models\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp\u003eEnergy balance signaling\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch3\u003eMusculoskeletal Research\u003c\/h3\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003cp\u003eMuscle protein synthesis pathways (experimental models)\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp\u003eConnective tissue regeneration studies\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp\u003eBone metabolism and remodeling research\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch3\u003eAging and Cellular Research\u003c\/h3\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003cp\u003eCellular regeneration pathways\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp\u003eAge-related GH decline models\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp\u003eMitochondrial function studies\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp\u003eTissue repair mechanisms\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch3\u003eNeuroendocrine Research\u003c\/h3\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003cp\u003eHypothalamic-pituitary axis regulation\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp\u003eNeurohormonal feedback loops\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp\u003eCentral regulation of growth signaling\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003chr\u003e\n\u003ch2\u003eTechnical Specifications\u003c\/h2\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eProperty\u003c\/th\u003e\n\u003cth\u003eCJC-1295 (No DAC)\u003c\/th\u003e\n\u003cth\u003eIpamorelin\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003ePeptide Name\u003c\/td\u003e\n\u003ctd\u003eCJC-1295 (No DAC)\u003c\/td\u003e\n\u003ctd\u003eIpamorelin\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eFunctional Class\u003c\/td\u003e\n\u003ctd\u003eGHRH Analog\u003c\/td\u003e\n\u003ctd\u003eGrowth Hormone Secretagogue\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAmino Acid Length\u003c\/td\u003e\n\u003ctd\u003e~29 amino acids\u003c\/td\u003e\n\u003ctd\u003e5 amino acids\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMolecular Weight\u003c\/td\u003e\n\u003ctd\u003e~3,363 Da\u003c\/td\u003e\n\u003ctd\u003e~711 Da\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMechanism\u003c\/td\u003e\n\u003ctd\u003eGHRH receptor agonist\u003c\/td\u003e\n\u003ctd\u003eGhrelin receptor agonist\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePrimary Target\u003c\/td\u003e\n\u003ctd\u003ePituitary GHRH receptor\u003c\/td\u003e\n\u003ctd\u003eGHS-R1a receptor\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAppearance\u003c\/td\u003e\n\u003ctd\u003eLyophilized powder\u003c\/td\u003e\n\u003ctd\u003eLyophilized powder\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eResearch Grade\u003c\/td\u003e\n\u003ctd\u003e≥98–99% (batch dependent)\u003c\/td\u003e\n\u003ctd\u003e≥98–99% (batch dependent)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003chr\u003e\n\u003ch2\u003eStability \u0026amp; Storage\u003c\/h2\u003e\n\u003ch3\u003eLyophilized Form\u003c\/h3\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003cp\u003eStore at \u003cstrong\u003e-20°C\u003c\/strong\u003e for long-term preservation\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp\u003eKeep protected from light and moisture\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp\u003eAvoid repeated freeze-thaw cycles\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch3\u003eReconstituted Solution\u003c\/h3\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003cp\u003eStore at \u003cstrong\u003e2–8°C\u003c\/strong\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp\u003eUse sterile handling procedures\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp\u003eStability varies depending on solvent and conditions\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch3\u003eStability Notes\u003c\/h3\u003e\n\u003cp\u003eBoth peptides are generally stable in lyophilized form under proper storage conditions. After reconstitution, degradation rates depend on temperature, solvent composition, and microbial control.\u003c\/p\u003e\n\u003chr\u003e\n\u003ch2\u003ePharmacokinetic Notes (Research Data)\u003c\/h2\u003e\n\u003ch3\u003eCJC-1295 (No DAC)\u003c\/h3\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003cp\u003eExtended but non-permanent GHRH receptor activity\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp\u003eShorter half-life compared to DAC-modified analogs\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp\u003eSupports intermittent GH release patterns\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch3\u003eIpamorelin\u003c\/h3\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003cp\u003eShort systemic half-life in experimental models\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp\u003eRapid receptor binding and signal activation\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp\u003eGH release typically observed in pulsatile form\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003e\u003cstrong\u003eNote:\u003c\/strong\u003e Both peptides primarily influence downstream hormonal cascades rather than maintaining sustained direct activity.\u003c\/p\u003e\n\u003chr\u003e\n\u003ch2\u003eSelected Research References \/ PubMed Keywords\u003c\/h2\u003e\n\u003cp\u003eResearchers may explore literature using the following keywords:\u003c\/p\u003e\n\u003ch3\u003eCJC-1295 (No DAC)\u003c\/h3\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003cp\u003eCJC-1295 no DAC\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp\u003egrowth hormone releasing hormone analog\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp\u003eGHRH receptor agonist peptide\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp\u003epulsatile growth hormone secretion\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch3\u003eIpamorelin\u003c\/h3\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003cp\u003eIpamorelin peptide\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp\u003egrowth hormone secretagogue receptor agonist\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp\u003eghrelin receptor GHS-R1a\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp\u003eselective GH release peptide\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch3\u003eCombined Research Topics\u003c\/h3\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003cp\u003eGHRH and ghrelin synergy\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp\u003egrowth hormone pulse amplitude\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp\u003eendocrine axis regulation peptides\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp\u003eIGF-1 stimulation research models\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003chr\u003e\n\u003ch2\u003eResearch Use Only Disclaimer\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003eFOR RESEARCH USE ONLY\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThis material is intended exclusively for laboratory research by qualified professionals.\u003c\/p\u003e\n\u003cp\u003eThis product:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003cp\u003eIs not approved for human use\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp\u003eIs not approved for veterinary use\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp\u003eIs not intended to diagnose, treat, cure, or prevent any disease\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp\u003eIs not a dietary supplement\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp\u003eMust not be used in clinical or therapeutic applications\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eAll information provided reflects published scientific literature and experimental research contexts. Results observed in vitro or in animal models may not translate to human physiology.\u003c\/p\u003e","brand":"NordBioLab","offers":[{"title":"Default Title","offer_id":57690361102668,"sku":null,"price":69.0,"currency_code":"EUR","in_stock":false}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/1058\/8363\/1948\/files\/nordbiolab-CJC-1295-IPAMORELIN.png?v=1781291602"}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/1058\/8363\/1948\/collections\/growth-factor-peptides.png?v=1781083225","url":"https:\/\/nordbiolab.com\/collections\/recovery-repair.oembed","provider":"NORDBIOLAB","version":"1.0","type":"link"}